#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Uterine leiomyosarcoma Anal cancer Microscopic polyangiitis Thrombotic microangiopathy Osteosarcoma Mitochondrial encephalomyopathy PIK3CA related overgrowth spectrum Thrombotic thrombocytopenic purpura Acute leukaemia Alexander disease Ehlers-Danlos syndrome Mucopolysaccharidosis I Nasopharyngeal cancer Gastrointestinal neuroendocrine tumour Hyperoxaluria More trials…

    Learn about Rare Diseases

    Activated PI3 kinase delta syndrome – Diagnostics Idiopathic pulmonary fibrosis Uterine leiomyosarcoma – Trials in Disease Mucous membrane pemphigoid – Basic Information Marfan’s syndrome Primary mediastinal large B-cell lymphoma Epidermolysis bullosa – Diagnostics Factor IX deficiency – Trials in Disease Ocular melanoma – Diagnostics Pemphigus – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sildenafil Citrate Bepirovirsen Lenacapavir Sodium L-Ascorbic Acid Technetium (99Mtc) Fenofibrate Micronised Nusinersen Domvanalimab Sugammadex Oxcarbazepine Agomelatine Sildenafil Metoprolol Decitabine TRV045 Abemaciclib Ipatasertib Dolutegravir Ibuprofen Lysine ZOREVUNERSEN SODIUM More therapies…

    Learn about Your Condition

    Epstein-Barr virus infection Stress cardiomyopathy Ventricular fibrillation Turner's syndrome Frontotemporal dementia Aortic stenosis Peripheral artery restenosis Obstructive pancreatitis Milk allergy Alcohol use disorder Sinusitis bacterial Ankylosing spondylitis Hepatic cancer Lymphocytic lymphoma Intellectual disability More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone receptor positive HER2 negative breast cancer

  • Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

    Recruiting

    1 1 1
    Investigated Diseases:
    • Biliary neoplasm
    • Malignant melanoma
    • Endometrial cancer
    Investigated Drugs:
    • Ifinatamab Deruxtecan
    Belgium France Germany Ireland Italy The Netherlands +3

  • Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Elacestrant
    • Betamethasone Sodium Phosphate
    • Goserelin Acetate
    Austria Czechia France Germany Greece Italy +1

  • Study on the Diagnostic Performance of 68Ga-ABS011 PET/CT for Patients with Metastatic Breast Cancer

    Recruiting

    4 1 1
    Investigated Diseases:
    • Neoplasm malignant
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • 68Ga-Nota-Abscint-Her2
    Austria Belgium

  • Study on Alisertib with Hormone Therapy for Patients with HR+, HER2- Recurrent or Metastatic Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Alisertib Sodium
    • Anastrozole
    • Exemestane
    Portugal Spain

  • Study on the Safety and Effects of Vosilasarm Alone and in Combination for Patients with Relapsed Advanced or Metastatic Breast Cancer

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Vosilasarm
    • Elacestrant
    Spain

  • Study on the Safety of AZD8421 Alone or with Drug Combination for Patients with Advanced Breast Cancer and High-Grade Ovarian Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Azd8421
    • Abemaciclib
    • Camizestrant
    Spain
Previous Page
1 2 3 4 5 … 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!